Christina Elisabeth Herder
Chief Executive Officer bei IDOGEN AB (PUBL)
Profil
Dr. Christina Elisabeth Herder is an Independent Director at Elicera Therapeutics AB, a Chief Executive Officer & Director at Idogen AB, a Deputy Director at Glycovisc BioTech AB and a Director at Medivir Personal AB.
She is on the Board of Directors at Elicera Therapeutics AB, Idogen AB and Herder Consulting AB.
Dr. Herder was previously employed as an Independent Director by PCI Biotech Holding ASA, a Chief Executive Officer by Modus Therapeutics AB, a Vice President-Licensing & Portfolio Management by Biovitrum AB, an Executive VP-Strategic Business Development by Medivir AB, a Chief Executive Officer by Modus Therapeutics Holding AB, and a Director-Corporate Development by Swedish Orphan Biovitrum AB.
She also served on the board at Akinion Pharmaceuticals AB and Ziccum AB.
She received her MBA from the University of Stockholm and a doctorate degree from Royal Institute of Technology.
Aktive Positionen von Christina Elisabeth Herder
| Unternehmen | Position | Beginn |
|---|---|---|
| IDOGEN AB (PUBL) | Chief Executive Officer | 01.09.2022 |
| ELICERA THERAPEUTICS AB | Director/Board Member | 01.01.2020 |
| Herder Consulting AB | Director/Board Member | - |
| Glycovisc BioTech AB | Corporate Officer/Principal | - |
| Medivir Personal AB | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Christina Elisabeth Herder
| Unternehmen | Position | Ende |
|---|---|---|
| PCI BIOTECH HOLDING ASA | Director/Board Member | 25.05.2023 |
| MEDIVIR AB | Corporate Officer/Principal | 01.12.2021 |
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Chief Executive Officer | 25.04.2017 |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Director/Board Member | 01.01.2014 |
| ░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Ausbildung von Christina Elisabeth Herder
| University of Stockholm | Masters Business Admin |
| Royal Institute of Technology | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 7 |
|---|---|
| PCI BIOTECH HOLDING ASA | Health Technology |
| MEDIVIR AB | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| MODUS THERAPEUTICS HOLDING AB | Health Technology |
| IDOGEN AB (PUBL) | Health Technology |
| ZICCUM AB | Health Technology |
| ELICERA THERAPEUTICS AB | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Biovitrum AB
 Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Commercial Services |
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Health Technology |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Health Technology |
| Medivir Personal AB | |
| Herder Consulting AB | |
| Glycovisc BioTech AB |
